Head-to-head evidence
HB0036 vs HLX301
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 / TIGIT · full Non-Small Cell Lung Cancer pipeline
HB0036
Developed by Shanghai Huaota Biopharmaceutical Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
HLX301
Developed by Shanghai Henlius Biotech
NCT05102214 · Phase 1/2 · status unknown
Patients were assigned to dose-escalation and expansion cohorts without randomization or blinding and without a control arm, so this cannot show whether HLX301 outperforms an alternative treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HB0036's landscape · HLX301's landscape